Stoke Therapeutics Inc (OQ:STOK)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 45 WIGGINS AVENUE
BEDFORD MA 01730
Tel: N/A
Website: https://www.stoketherapeutics.com
IR: See website
<
Key People
Edward M. Kaye
Chief Executive Officer, Director
Stephen J. Tulipano
Chief Financial Officer
Huw M. Nash
Chief Operating Officer, Chief Business Officer
Jonathan Allan
General Counsel, Company Secretary
Barry S. Ticho
Chief Medical Officer
 
Business Overview
Stoke Therapeutics, Inc. is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with ribonucleic acid-based medicines. Using its Targeted Augmentation of Nuclear Gene Output (TANGO) approach, the Company is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both the occurrence of seizures and non-seizure comorbidities. Its STK-002 is a ASO in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene.
Financial Overview
For the fiscal year ended 31 December 2023, Stoke Therapeutics Inc revenues decreased 29% to $8.8M. Net loss increased 4% to $104.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 5% to $72.3M (expense), Stock-based Compensation in SGA increase of 10% to $15.3M (expense).
Employees: 110 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $423.71M as of Dec 31, 2023
Annual revenue (TTM): $8.78M as of Dec 31, 2023
EBITDA (TTM): -$112.30M as of Dec 31, 2023
Net annual income (TTM): -$104.70M as of Dec 31, 2023
Free cash flow (TTM): -$82.68M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 46,303,743 as of Mar 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.